Who is sponsoring NCT06446752?

NCT06446752 is sponsored by University of Washington.

What condition does NCT06446752 study?

NCT06446752 studies Gonorrhea, Gonorrhea of Pharynx, Gonorrhea of Anus, Gonorrhea of Cervix.

What drugs are being tested in NCT06446752?

Interventions: Bexsero, Placebo.

What is the status of NCT06446752?

NCT06446752 is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2025-07-07 · How we verify

A Phase 3 Randomized, Observer-Blind, Placebo-Controlled Study to Assess Efficacy of Meningococcal Group B (rMenB+OMV NZ (Bexsero)) in Preventing Gonococcal Infection Among South African Cis-Gender Women

NCT06446752 Phase 3 ACTIVE_NOT_RECRUITING

This proposed 2-arm randomized evaluation of two doses of 4CMenB vaccine versus placebo at Enrollment and Month 2 is designed as a proof-of-concept study to inform potential use for dual meningococcal B and gonococcal prevention, and to inform Neisseria gonorrheae vaccine development.

Details

Lead sponsor	University of Washington
Phase	Phase 3
Status	ACTIVE_NOT_RECRUITING
Enrolment	1100
Start date	2024-08-14
Completion	2027-01

Conditions

Gonorrhea
Gonorrhea of Pharynx
Gonorrhea of Anus
Gonorrhea of Cervix

Interventions

Bexsero
Placebo

Primary outcomes

First diagnosis of gonorrhea at cervical or anorectal sites occurring greater than or equal to 1 month after the second vaccination with study product through to the study end — 18 months
Assess efficacy of Bexsero in prevention of cervical and/or anorectal gonococcal infection

Countries

South Africa